Chromadex Corp (CDXC) Scheduled to Post Earnings on Wednesday
Chromadex Corp (OTCMKTS:CDXC) will post its quarterly earnings results after the market closes on Wednesday, November 8th. Analysts expect Chromadex Corp to post earnings of ($0.03) per share for the quarter.
Chromadex Corp (OTCMKTS:CDXC) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.09). The company had revenue of $5.31 million for the quarter, compared to analyst estimates of $11.00 million. Chromadex Corp had a negative return on equity of 63.19% and a negative net margin of 52.09%. On average, analysts expect Chromadex Corp to post $-0.19 EPS for the current fiscal year and $0.01 EPS for the next fiscal year.
Shares of Chromadex Corp (CDXC) opened at 4.09 on Wednesday. Chromadex Corp has a 12-month low of $2.25 and a 12-month high of $4.85. The firm’s market capitalization is $188.52 million. The stock has a 50 day moving average price of $4.31 and a 200 day moving average price of $3.60.
Several equities analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Chromadex Corp in a research report on Monday, October 2nd. Ladenburg Thalmann Financial Services assumed coverage on Chromadex Corp in a research report on Monday, September 25th. They set a “buy” rating and a $7.00 price objective for the company. ValuEngine upgraded Chromadex Corp from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. Finally, Zacks Investment Research downgraded Chromadex Corp from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $6.33.
In related news, insider Robert N. Fried acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was bought at an average price of $3.15 per share, for a total transaction of $31,500.00. Following the transaction, the insider now owns 583,241 shares of the company’s stock, valued at $1,837,209.15. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Step Holdings Ltd Pioneer acquired 786,167 shares of the business’s stock in a transaction dated Friday, August 18th. The shares were bought at an average price of $2.60 per share, with a total value of $2,044,034.20. The disclosure for this purchase can be found here. Insiders acquired 798,167 shares of company stock valued at $2,082,154 over the last 90 days.
Chromadex Corp Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Receive News & Ratings for Chromadex Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex Corp and related companies with MarketBeat.com's FREE daily email newsletter.